Piramal Pharma Future Growth
Future criteria checks 4/6
Piramal Pharma is forecast to grow earnings and revenue by 84.5% and 11.4% per annum respectively. EPS is expected to grow by 84.4% per annum. Return on equity is forecast to be 8.1% in 3 years.
Key information
84.5%
Earnings growth rate
84.43%
EPS growth rate
| Pharmaceuticals earnings growth | 16.5% |
| Revenue growth rate | 11.4% |
| Future return on equity | 8.05% |
| Analyst coverage | Good |
| Last updated | 30 Apr 2026 |
Recent future growth updates
Analysis Article • Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price
Piramal Pharma Limited ( NSE:PPLPHARMA ) just released its latest quarterly report and things are not looking great. It...Analysis Article • May 17
Piramal Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Piramal Pharma Limited ( NSE:PPLPHARMA ) came out with its annual results last week, and we wanted to see how the...Recent updates
Narrative Update • Apr 24
PPLPHARMA: Future Upside Will Stem From ADC Milestones And Portfolio Expansion
Analysts have kept their Piramal Pharma fair value estimate unchanged at ₹200.10. This reflects broadly steady assumptions on growth, margins and future P/E that together keep the price target in line with prior views.Narrative Update • Apr 09
PPLPHARMA: Future Upside Will Stem From ADC Platform And Portfolio Expansion
Analysts have trimmed their price target for Piramal Pharma from ₹204.60 to ₹200.10, citing updates to long term assumptions on revenue growth and profit margins, as well as a slightly lower future P/E multiple. What's in the News Piramal Pharma Solutions completed its 1,500th antibody drug conjugate batch at its Grangemouth, UK bioconjugate facility.Narrative Update • Mar 26
PPLPHARMA: Future Upside Will Stem From Acquisitions And Portfolio Expansion
Narrative update on Piramal Pharma price target The analyst fair value estimate for Piramal Pharma is maintained at ₹204.6 per share, with analysts citing unchanged assumptions on discount rate, revenue growth, profit margin and future P/E to support keeping the target steady. What's in the News Piramal Pharma Solutions completed its 1,500th antibody drug conjugate batch at the Grangemouth, UK bioconjugate development and manufacturing site, marking a commercial oncology ADC batch and underlining the facility's role in proof of concept, clinical, and commercial-scale production (Key Developments).Narrative Update • Mar 11
PPLPHARMA: Future Upside Will Stem From Acquisitions And Portfolio Expansion
Analysts have kept their fair value estimate for Piramal Pharma steady at ₹204.6 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, and so the overall analyst price target remains effectively unchanged. What's in the News Piramal Pharma plans to keep pursuing acquisitions, along with co development and licensing, to add products to its portfolio as part of its overall growth plan, according to Global Pharma CEO Peter DeYoung (Key Developments).Narrative Update • Feb 25
PPLPHARMA: Future Upside Will Stem From Portfolio Expansion And Compliance Progress
Analysts have kept Piramal Pharma's fair value estimate steady at ₹204.6 while trimming the assumed future P/E multiple from 36.72x to 29.82x, reflecting a more conservative view on how much investors may eventually be willing to pay for its earnings. What's in the News Piramal Pharma plans to look for acquisitions, with CEO Peter DeYoung highlighting co-development, licensing, and acquisitions as key ways to add to the portfolio alongside growth in the existing base business, including the inhalation portfolio outside the U.S. as more markets are registered from the Digwal facility (Key Developments).Narrative Update • Feb 09
PPLPHARMA: Future Upside Will Stem From Inhalation Portfolio And Compliance Progress
Analysts have trimmed their fair value estimate for Piramal Pharma from ₹234.9 to ₹204.6, citing updated assumptions that reflect slightly more conservative revenue growth and P/E expectations, along with a modest adjustment in the discount rate and profit margin outlook. What's in the News Piramal Pharma plans to pursue acquisitions, co development and licensing opportunities to add to its portfolio, alongside efforts to grow its existing base business.Analysis Article • Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price
Piramal Pharma Limited ( NSE:PPLPHARMA ) just released its latest quarterly report and things are not looking great. It...Narrative Update • Jan 24
PPLPHARMA: Future Upside Will Stem From ADC Collaboration Progress
Analysts have trimmed their fair value estimate for Piramal Pharma to ₹234.90 from ₹239.90, reflecting slightly softer assumptions on revenue growth, profit margins and the future P/E multiple. What's in the News Piramal Pharma has scheduled a board meeting on January 28, 2026 to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Analysis Article • Jan 15
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Jan 08
PPLPHARMA: Future Upside Will Stem From ADC Collaboration Momentum
Analysts have lowered their fair value estimate for Piramal Pharma from ₹244.33 to ₹239.90, citing updated assumptions around revenue growth, profit margin and future P/E expectations. What's in the News Piramal Pharma Limited has scheduled a Special or Extraordinary Shareholders Meeting via postal ballot in India on January 16, 2026.Narrative Update • Dec 21
PPLPHARMA: Future Upside Will Stem From ADC Development Momentum
Analysts have modestly adjusted their price target for Piramal Pharma to ₹244.33 per share, reflecting steady assumptions on growth, margins, and valuation multiples, while maintaining confidence in the company’s long term earnings trajectory. What's in the News Piramal Pharma Solutions has completed its transition to full compliance with evolving global nitrosamine impurity requirements, investing in in house and external testing capabilities to help ensure product safety and regulatory alignment (Key Developments).Narrative Update • Dec 07
PPLPHARMA: Medium Term Execution Will Drive Upside From ADC Collaboration
Analysts have modestly revised their price target for Piramal Pharma to Rs 244.33, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future valuation multiples, while incorporating incremental confidence in the company’s medium term execution. What's in the News Piramal Pharma Solutions has completed its global nitrosamine compliance program, with all existing commercial products now meeting regulatory standards and enhanced in house and external testing capabilities in place (Key Developments).Narrative Update • Nov 23
PPLPHARMA: Collaboration Momentum Will Drive Broader Opportunities in the Coming Year
Analysts have maintained their price target for Piramal Pharma at ₹244.33. They cite modest upward revisions to revenue growth estimates, which are offset by a slight decrease in projected profit margins and a higher future price-to-earnings ratio.Narrative Update • Nov 08
PPLPHARMA: New Partnerships Will Drive Future Sector Expansion
Analysts have revised Piramal Pharma's fair value estimate down from ₹258.67 to ₹244.33 per share. This change reflects updated assumptions about revenue growth and profit margins.Analysis Article • Nov 06
The Price Is Right For Piramal Pharma Limited (NSE:PPLPHARMA)
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in India, you could be...Analysis Article • Sep 10
A Look At The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Piramal Pharma's estimated fair value is ₹173 based on 2 Stage Free Cash Flow to Equity With ₹198 share...Analysis Article • Jul 09
Why Investors Shouldn't Be Surprised By Piramal Pharma Limited's (NSE:PPLPHARMA) P/S
There wouldn't be many who think Piramal Pharma Limited's ( NSE:PPLPHARMA ) price-to-sales (or "P/S") ratio of 2.9x is...Analysis Article • Jun 13
Piramal Pharma (NSE:PPLPHARMA) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 17
Piramal Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Piramal Pharma Limited ( NSE:PPLPHARMA ) came out with its annual results last week, and we wanted to see how the...Analysis Article • Mar 08
Piramal Pharma Limited (NSE:PPLPHARMA) Investors Are Less Pessimistic Than Expected
When close to half the companies in the Pharmaceuticals industry in India have price-to-sales ratios (or "P/S") below...Analysis Article • Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Piramal Pharma Limited ( NSE:PPLPHARMA ) released its quarterly result to the...
New Narrative • Dec 19
CDMO Innovations And Lexington Facility Expansion Will Catalyze Market Growth And Boost Earnings
Strategic investments in facility expansion and hospital generics, along with cost optimization, aim to drive growth and sustain healthy EBITDA margins.Analysis Article • Oct 26
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
It's been a good week for Piramal Pharma Limited ( NSE:PPLPHARMA ) shareholders, because the company has just released...Analysis Article • Oct 25
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jul 14
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jun 17
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Piramal Pharma's estimated fair value is ₹133 based on 2 Stage Free Cash Flow to Equity Piramal Pharma's...Analysis Article • May 21
We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
Piramal Pharma Limited's ( NSE:PPLPHARMA ) stock was strong after they recently reported robust earnings. We did some...Analysis Article • Mar 26
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
With a median price-to-sales (or "P/S") ratio of close to 2.3x in the Pharmaceuticals industry in India, you could be...Analysis Article • Feb 28
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Piramal Pharma fair value estimate is ₹141 Piramal Pharma's...Analysis Article • Feb 02
Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Last week, you might have seen that Piramal Pharma Limited ( NSE:PPLPHARMA ) released its quarterly result to the...Analysis Article • Nov 09
Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights The projected fair value for Piramal Pharma is ₹144 based on 2 Stage Free Cash Flow to Equity Piramal...Analysis Article • Aug 11
Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Piramal Pharma fair value estimate is ₹123 Current share price...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2029 | 127,507 | 7,399 | 5,980 | 16,614 | 5 |
| 3/31/2028 | 115,507 | 5,295 | 5,739 | 14,028 | 11 |
| 3/31/2027 | 100,911 | 1,802 | 1,564 | 10,473 | 11 |
| 3/31/2026 | 88,691 | -3,259 | 7,626 | 16,526 | N/A |
| 12/31/2025 | 88,714 | -1,636 | N/A | N/A | N/A |
| 9/30/2025 | 89,357 | -237 | 7,599 | 15,974 | N/A |
| 6/30/2025 | 91,338 | 981 | N/A | N/A | N/A |
| 3/31/2025 | 91,512 | 911 | 2,279 | 8,923 | N/A |
| 12/31/2024 | 89,495 | 389 | N/A | N/A | N/A |
| 9/30/2024 | 87,038 | 453 | -310 | 6,810 | N/A |
| 6/30/2024 | 83,735 | 278 | N/A | N/A | N/A |
| 3/31/2024 | 81,712 | 178 | 2,925 | 10,045 | N/A |
| 12/31/2023 | 78,435 | -333 | N/A | N/A | N/A |
| 9/30/2023 | 76,009 | -1,336 | -992 | 8,655 | N/A |
| 6/30/2023 | 74,096 | -1,760 | N/A | N/A | N/A |
| 3/31/2023 | 70,816 | -1,865 | -4,809 | 4,839 | N/A |
| 12/31/2022 | 72,228 | -325 | -6,634 | 3,382 | N/A |
| 9/30/2022 | 69,535 | 2,210 | N/A | N/A | N/A |
| 6/30/2022 | 67,532 | 2,626 | N/A | N/A | N/A |
| 3/31/2022 | 67,341 | 3,760 | -1,231 | 7,664 | N/A |
| 3/31/2021 | 58,868 | 7,708 | -43 | 5,516 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPLPHARMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.9%).
Earnings vs Market: PPLPHARMA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PPLPHARMA is expected to become profitable in the next 3 years.
Revenue vs Market: PPLPHARMA's revenue (11.4% per year) is forecast to grow faster than the Indian market (11% per year).
High Growth Revenue: PPLPHARMA's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPLPHARMA's Return on Equity is forecast to be low in 3 years time (8.1%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/09 09:03 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Piramal Pharma Limited is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |